This company listing is no longer active
ESP Stock Overview
Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Esperite N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0092 |
| 52 Week High | €0.032 |
| 52 Week Low | €0.009 |
| Beta | 0 |
| 1 Month Change | -22.03% |
| 3 Month Change | -56.60% |
| 1 Year Change | -66.67% |
| 3 Year Change | -82.34% |
| 5 Year Change | -98.37% |
| Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| ESP | NL Biotechs | NL Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | 0.8% |
| 1Y | -66.7% | -11.3% | 18.0% |
Return vs Industry: ESP underperformed the Dutch Biotechs industry which returned -19.8% over the past year.
Return vs Market: ESP underperformed the Dutch Market which returned -27.8% over the past year.
Price Volatility
| ESP volatility | |
|---|---|
| ESP Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in NL Market | 7.5% |
| 10% least volatile stocks in NL Market | 2.2% |
Stable Share Price: ESP's share price has been volatile over the past 3 months.
Volatility Over Time: ESP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Dutch stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Frédéric Amar | www.esperite.com |
Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord.
Esperite N.V. Fundamentals Summary
| ESP fundamental statistics | |
|---|---|
| Market cap | €481.41k |
| Earnings (TTM) | -€18.72m |
| Revenue (TTM) | €13.57m |
0.0x
P/S Ratio0.0x
P/E RatioIs ESP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ESP income statement (TTM) | |
|---|---|
| Revenue | €13.57m |
| Cost of Revenue | €4.50m |
| Gross Profit | €9.07m |
| Other Expenses | €27.78m |
| Earnings | -€18.72m |
Last Reported Earnings
Jun 30, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ESP perform over the long term?
See historical performance and comparison